A randomized, open-label study of the addition of oral Xeloda [capecitabine] to intravenous Taxotere [docetaxel] and epirubicin on progression-free survival in patients with advanced breast cancer.

Trial Profile

A randomized, open-label study of the addition of oral Xeloda [capecitabine] to intravenous Taxotere [docetaxel] and epirubicin on progression-free survival in patients with advanced breast cancer.

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Feb 2010

At a glance

  • Drugs Capecitabine; Docetaxel; Epirubicin
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 10 Jul 2008 Results for 271 stage IV patients have been reported at ASCO 2008 (1112144).
    • 17 Oct 2007 Status changed from in progress to completed.
    • 01 Jun 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top